In this episode of MedInsights Unleashed, Patrick R. Coyle MBA, joins John Collins to discuss the complexities of healthcare access and affordability. Together, they explore how patients can better understand the prescription journey, navigate insurance denials, utilize available support programs, and become stronger advocates for their own care.

In this episode of MedInsights Unleashed, Prof. Philip Philip, Professor of Medical Oncology, Wayne State University School of Medicine and Henry Ford Cancer Institute, discusses how targeting KRAS mutations may change the treatment landscape for pancreatic cancer, reviews the final ASCO analysis, and explains what these findings mean for patients, caregivers, and clinicians. While not a cure, the study offers new hope by extending survival, improving quality of life, and opening the door to a new era of targeted therapy research.

The discussion explores the challenges of locally invasive thyroid cancer and how neoadjuvant lenvatinib prior to surgery may help improve surgical outcomes, reduce morbidity, and preserve critical structures such as the recurrent laryngeal nerve.

The conversation also highlights findings from a multicenter Phase 2 clinical trial, including promising results related to nerve preservation, vocal cord recovery, and the future of multidisciplinary thyroid cancer care.

The discussion explores CPR fundamentals, CPR-102 updates, AED use, DNR considerations, and why rapid intervention by both healthcare professionals and members of the community can significantly improve outcomes during cardiac emergencies.

Drawing from his experience in Emergency Medical Services, law enforcement, and EMS education, Devin provides practical insights into emergency response, first responder training, and the importance of public awareness and preparedness.

This episode offers valuable information for healthcare professionals, caregivers, first responders, and members of the public who want a better understanding of CPR and emergency response.

The discussion explores aortic stenosis, the evolution of TAVR, and the emerging science and MRI data surrounding DurAVR THV, including the potential importance of flow dynamics, laminar flow, durability, and long-term valve performance.

We also discuss patient selection, future valve innovation, and how next-generation technologies may move beyond simply treating obstruction toward restoring more natural cardiovascular physiology.

The conversation explores the complex system behind drug access—including insurance coverage, copays, prior authorizations, and the role of pharmacies. Patrick provides insight into how financial and operational factors influence whether patients ultimately receive their prescribed treatment.

The discussion also highlights key differences between branded and generic medications, the growing challenges in specialty therapies like oncology, and the importance of patient advocacy.

This episode offers practical guidance for patients and caregivers on how to navigate the system, ask the right questions, and better understand the realities behind prescription access.

The conversation explores the changing role of transarterial chemoembolization (TACE) in intermediate-stage disease, emerging clinical evidence from studies such as REPLACEMENT Emerald-1 and LEAP-012, and how new systemic and immunotherapy approaches are reshaping treatment decisions. The discussion also highlights the importance of curative opportunities, multidisciplinary care, and maintaining overall survival as the most meaningful endpoint in liver cancer treatment.

The conversation explores electrically enhanced transforaminal lumbar interbody fusion (e-TLIF), which combines spinal stabilization with targeted nerve stimulation, as well as broader trends in non-opioid pain management, minimally invasive surgery, robotics, and AI shaping modern spine care.

Our guests are Bill Niland, CEO of ReGelTec Inc., and Dr. Anthony Lowman, PhD, Professor of Biomedical Engineering and Co-Founder/Chief Medical Officer at ReGelTec. They walk us through the science, creation, and development of this injectable hydrogel technology. Hydrafil is designed to help patients with lumbar back pain by restoring hydration and pressure inside the spinal disc, supporting its structure, and potentially reducing inflammation and pain.

ReGelTec has launched its pivotal HYDRAFIL-D Study, a multicenter, randomized U.S. trial enrolling ~225 patients. For details, visit ClinicalTrials.gov and search: Degenerative Disc Disease + Hydrafil (NCT06011551 and NCT04984629).

The discussion highlights early results from trials combining immunotherapy and chemotherapy before standard treatment, showing promising improvements in tumor response while reducing long-term side effects. This research is shaping the future of HPV-related head and neck cancer care and could change how clinicians plan treatments—bringing us closer to a more precise and less invasive approach.

The discussion also covers emerging research into KRAS, common DNA mutation in tumors that is playing a major role in changing future targeted treatment strategies. With perspectives from both U.S. and global healthcare systems, this episode emphasizes the power of awareness, timely action, and the promise of personalized medicine in improving outcomes for patients.

Eric provides critical insights into the life-saving role of Narcan, the challenges EMS teams face in overdose response, and the alarming prevalence of drug use in schools. As volunteer EMT numbers decline, hybrid staffing models are becoming the new norm. This conversation serves as a wake-up call, underscoring the urgent need for awareness, prevention, and preparedness in combating the street drug epidemic.

4o

This is the second episode in our series on colorectal cancer. In this episode of MedInsights Unleashed, we sit down with Prof. Paulo Hoff, MD, PhD, from the University of São Paulo, Brazil, to discuss the latest developments in colorectal cancer treatment. With cases increasing, especially among younger adults, the conversation underscores the importance of early screening and detection. Prof. Hoff explains how tumor location—right vs. left side—affects treatment strategies, the role of genetic markers in guiding decisions, and how immunotherapy is shaping new treatment options. Listeners will gain a clearer understanding of molecular profiling, personalized care, and what these advancements mean for patients facing colorectal cancer.

This episode uncovers misconceptions, risk factors, and treatment options, including an unexpected dietary ally—prunes. Recent research suggests that daily prune consumption may help maintain bone density and support fracture healing, making it a promising nonpharmacologic approach to osteoporosis prevention.

👉 If you think osteoporosis only affects women, think again.

The discussion covers the complete treatment journey, from initial diagnosis through staging—which determines both local and distant tumor spread—to help create optimal treatment plans. Dr. Hoff explains that some patients may require temporary or permanent colostomy procedures.

A significant focus is placed on the emerging total neoadjuvant treatment (TNT) approach, which administers all chemotherapy and radiation before surgery to improve outcomes. The episode concludes by emphasizing the value of collaborative care, bringing together different oncology specialists for comprehensive treatment

 Qualisure Diagnostics Inc contact information:

Oliver F. Bathe, MD - CEO & Founder

3655 36th Street NW Calgary, Alberta T2L 1Y8

p: +1 403.614.7124

e:  obathe@qualisuredx.com | www.qualisuredx.com

- **Cutting-Edge Therapies:** Explore the transformation in HCC treatment from surgery and transplantation to the latest immunotherapies. Discover how IV therapies demonstrate superior efficacy and manageable toxicity compared to oral options.

- **Checkmate 9DW Trial Insights:** Get an in-depth analysis of the pivotal Checkmate 9DW trial, comparing immunotherapy agents (Nivolumab and Ipilimumab) with tyrosine kinase inhibitors (lenvatinib or sorafenib). Learn about the trial's diverse patient population and the critical role of alpha fetoprotein as a prognostic marker.

- **Combination vs. Monotherapy:** Hear why combination therapies are setting new benchmarks in complete response rates and overall survival, offering new hope for liver cancer patients.

- **Multidisciplinary Approach:** Understand the crucial role of multidisciplinary teams in navigating complex decisions involving liver transplantation, intra-arterial therapies, and systemic treatments.

- **Patient Management and Outcomes:** Discover the significance of early side-effect management and patient education in improving long-term outcomes, reducing treatment visits, and enhancing quality of life.

Professor Vogel discusses the differences in treatment access between Germany and Canada, having experienced both healthcare systems. He highlights the restrictive criteria for liver transplantation in Germany and the limited availability of certain therapies in Canada, particularly for rare cancers like cholangiocarcinoma. The discussion delves into the ethical implications of withholding potentially life-saving treatments and the need for a more streamlined and patient-centered approach to reimbursement. Financial toxicity is also examined, as well as the role of patient advocacy in driving change and ensuring timely access to treatment.

The transcript concludes with a call to action for patients and healthcare professionals to advocate for improved access to the right treatment at the right time.

In this first episode, hosts Zahra and John are joined by Professor Arndt Vogel to discuss key data from the adjuvant setting of liver cancer. They talk about the challenges of liver cancer treatment, the high mortality rate associated with the disease, and the progress made in recent years.

Professor Vogel provides an overview of the IMbrave 050 study, which was designed to investigate the efficacy of an adjuvant treatment combination of the checkpoint inhibitor atezolizumab and the targeted therapy bevacizumab in delaying or preventing recurrence compared with active surveillance. The study shows promising results in terms of improved recurrence-free survival, but longer follow up is needed to determine its impact on overall survival. The conversation also touches on the safety profile of the treatment and the importance of multidisciplinary teams in decision-making.